Elena Z.
- Country
- Italy
- Department
- SOC Oncologia Medica
Research Overview
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
- Phase 3 Study of LY4170156 (Sofetabart Mipitecan) ± Bevacizumab versus standard chemotherapy in platinum‑resistant and platinum‑sensitive ovarian cancer
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
Data & Insights
Has run more than one trial at 137 of 286 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced gynecological malignancies, with particular expertise in managing various forms of ovarian cancer including epithelial ovarian, fallopian tube, and primary peritoneal cancers.
- Advanced Endometrial Cancer
- Recurrent Ovarian Cancer
- Low-grade Serous Epithelial Carcinoma
Their work encompasses both platinum-sensitive and platinum-resistant disease states.
Therapeutic Approaches
The investigator focuses on innovative treatment strategies including targeted therapies and maintenance treatments for gynecologic cancers.
- Hormone Receptor-Targeted Treatments
- Immunotherapy Combinations
- Novel Drug Combinations
Their research includes evaluation of both established and emerging therapeutic agents.
Treatment Optimization
The investigator works on developing personalized treatment approaches based on specific biomarkers and patient characteristics.
- Biomarker-Driven Therapy
- Treatment Sequencing
- Maintenance Strategies
Their research emphasizes improving survival outcomes through targeted therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.